Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire PLC    SHP   JE00B2QKY057


Delayed Quote. Delayed  - 07/25 05:35:01 pm
4870 GBp   -0.90%
07/21 SHIRE : Launches Paediatric Indication For HyQvia Across Europe
07/20DJSHIRE : Files 8K - Other Events
07/13 TEARLAB CORPORA : Comments on Shire plc FDA Approval of Xiidra (lifi..
News SummaryMost relevantAll newsSector news 

Shire Plc. : Shire Buying Pervasis To Advance Regenerative Medicines Business

share with twitter share with LinkedIn share with facebook
share via e-mail
04/12/2012 | 05:49pm CEST
  By Sten Stovall 

Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative medicine business.

A specialist in hyperactivity and rare genetic diseases, Shire is also expanding its activities in regenerative medicine to find products for replacing human cells, tissues or organs to restore or establish normal function.

Toward that end, Shire on Thursday said it will pay Pervasis an undisclosed upfront payment, plus milestones if Pervasis' lead product, a cell-based therapy called Vascugel, hits certain clinical, regulatory and sales targets. No financial terms were disclosed.

Pervasis, based in Cambridge, Massachusetts, is developing acute vascular repair technologies for patients with end-stage renal disease, or ESRD, which is an advanced and irreversible kidney disease. There are around 600,000 people in the U.S. and more than 250,000 in the EU currently being treated for ESRD.

Shire said its deal with Pervasis will make a strong strategic fit with its existing Dermagraft treatment for diabetic foot ulcers.

Diabetes is the chief cause of ESRD, while diabetic patients on dialysis have a greater risk of developing a diabetic foot ulcer than diabetics not receiving dialysis treatment.

Shire's head of regenerative medicine, Kevin Rakin, said that "this acquisition marks a very important step for Shire in building a regenerative medicine business focused on tissue repair and regeneration."

He told Dow Jones Newswires that Vascugel is currently in mid-stage clinical trials and will be progressing to late-stage Phase III testing soon. Vascugel has received Orphan Product designation from the U.S. Food and Drug Administration and from the European Medical Agency. If all goes well, marketing authorization could be sought for Vascugel by 2017, Rakin said.

Pervasis will give Shire a new cell-based technology platform called endothelial cell technology that has global potential. "We are looking at generating other products out of this platform," Rakin said.

"We're building our regenerative medicine activities because we believe it's one of the next big areas of medicine and so this adds to the Dermagraft purchase and we're building up our pipeline now. We're committed to doing this."

- By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE PLC
07/21 SHIRE : Launches Paediatric Indication For HyQvia Across Europe
07/20DJSHIRE : Files 8K - Other Events
07/20 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
07/13 TEARLAB CORPORATION : Comments on Shire plc FDA Approval of Xiidra (lifitegrast ..
07/12DJMARKET SNAPSHOT : Dow, S&P 500 Sprint To Fresh Records
07/12DJSHIRE : Files 8K - Other Events
07/12 Shire on a roll as U.S. approves keenly awaited eye drug
07/12 TOP NEWS SUMMARY : Shire's Xiidra Dry-Eye Treatment Gains US Approval
07/12 SHIRE : Shares Up On US Approval For Dry Eye Treatment
07/12 LONDON MARKET OPEN : Shire Rises After US Approval For Eye Treatment
More news
Sector news : Pharmaceuticals - NEC
07/25DJGilead Sales of Hepatitis C Drugs Fall 19%
07/25DJSTADA ARZNEIMITTEL : Feels More Heat From Active Ownership
07/25DJASTRAZENECA : 2Q 2016 -- Forecast
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/25 The Strong Often Get Stronger!
07/25 Is Biotech Finally Ready To Move Higher?
07/25 European Ad Comm backs Merrimack and Shire's Onivyde for pancreatic cancer
07/22 Biogen Needs To Fill Pipeline Or Rethink Strategy
07/20 Chronos Therapeutics takes over three pre-clinical CNS programs from Shire
Financials ($)
Sales 2016 10 697 M
EBIT 2016 4 078 M
Net income 2016 2 036 M
Debt 2016 17 829 M
Yield 2016 0,45%
P/E ratio 2016 19,45
P/E ratio 2017 15,46
EV / Sales 2016 7,03x
EV / Sales 2017 4,77x
Capitalization 57 372 M
More Financials
Duration : Period :
Shire PLC Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Full-screen chart
Technical analysis trends SHIRE PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 80,3 $
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
David R. Ginsburg Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE PLC3.66%57 372
JOHNSON & JOHNSON21.58%343 528
PFIZER INC.13.94%223 065
NOVARTIS AG-5.13%218 815
ROCHE HOLDING LTD.-9.62%217 668
MERCK & CO., INC.10.87%162 096
More Results